Megestrol acetate

DB00351
Approved Indication

For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Can

2 Targets
0 Resistance Mutations
5 References
3D Structure No structure available
No co-crystal structure available
Mechanism of Action

The precise mechanism by which megestrol acetate produces effects in anorexia and cachexia is unknown at the present time, but its progestin antitumour activity may involve suppression of luteinizing hormone by inhibition of pituitary function. Studies also suggest that the megestrol's weight gain effect is related to its appetite-stimulant or metabolic effects rather than its glucocorticoid-like effects or the production of edema. It has also been suggested that megestrol may alter metabolic pathyways via interferences with the production or action of mediators such as cachectin, a hormone that inhibits adipocyte lipogenic enzymes.

Details
DrugBank ID DB00351 ↗
Approval Date 1988-08-08
Molecular Weight 384.516 g/mol
Drug Class Other
ATC Codes L02AB01, G03AA04, G03DB02, G03AC05, G03FA08, G03AB01, G03FB04
Synonyms MGA
SMILES
[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C
ADMET Profile
Computing properties…